CMSMedicaidPart D/Prescription DrugsPrice Transparency

CMS proposes rules to improve Medicaid drug price transparency

(By Rylee Wilson for Becker’s Hospital Review)

CMS is proposing a set of rules for drug manufacturers, pharmaceutical benefit managers and managed care plans to increase drug price transparency in Medicaid.

In a proposed rule published May 23, the agency laid out plans to increase transparency by requiring manufacturers to disclose some pricing information through a price survey and requiring PBMs to disclose more pricing details to managed care plans. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or

Leave a Reply